Our history

A remarkable story of giant steps forward and focused endeavor

Nykode Therapeutics ASA (Oslo Stock Exchange (OSE): NYKD) is a listed, clinical-stage biopharmaceutical company, dedicated to the discovery and development of vaccines and novel immunotherapies. The company is based on the technology conceived and developed at the University of Oslo and Oslo University Hospital in the laboratory of Professor Bjarne Bogen, with contributions from Professor Inger Sandlie.

Nykode Therapeutics has developed a unique and innovative modular technology platform, targeting antigen to Antigen Presenting Cells, with the aim to treat and prevent cancer as well as infectious diseases. Through its innovative design, Nykode’s proprietary vaccine platform generates fast, strong, long-lasting and broad antibody and T cell responses, leading to remarkably potent vaccines and immunotherapies.


November 2006

Nykode Therapeutics ASA was founded under the name Vaccibody AS.

December 2014

Nykode Granted Platform Patent by European Patent Office.

January 2015

Nykode Granted Platform Patent by the U.S. Patent Office.

September 2015

Nykode announces vaccination of first patient in its Phase I/IIa study with VB10.16 immunotherapy for patients with HPV16 induced high-grade lesions of the cervix.

August 2016

Nykode announces positive results from the Phase I part of the clinical trial VB C-01 in patients with high-grade cervical dysplasia and received a recommendation by the cohort review committee as well as the independent data monitoring board to continue to the expansion Phase (IIa).

December 2016

Nykode successfully completed Private Placement of NOK 220 million.

March 2017

Nykode announces vaccination of first patient in its Phase IIa study with VB10.16 immunotherapy for patients with HPV16 induced high-grade lesions of the cervix.

June 2017

Nykode announces positive results from the Phase I part of the clinical trial VB C-01, a first human dose, open-label, multicenter Phase I/IIa study of VB10.16 immunotherapy for the treatment of high-grade Cervical Intraepithelial Neoplasia.

April 2018

Nykode announces informed consent signed by the first patient and enrollment process initiated in the cancer neoantigen Phase I/IIa clinical trial.

September 2018

Nykode announces a new clinical collaboration with Nektar Therapeutics to evaluate Nykode’s personalized cancer neoantigen vaccine, VB10.NEO, in combination with Nektar’s CD-122-biased agonist, NKTR-214.

Nykode announces positive 6-months interim results from the Phase IIa part of the clinical study VB C-01.

February 2019

Nykode enters into a collaboration with Roche to explore a combination of Nykode’s VB10.16 and immune-checkpoint inhibitor atezolizumab (Tecentriq®) in advanced cervical cancer.

Nykode successfully conducts a private placement, raising around NOK 230 million (EUR 23.6 million).

March 2019

Nykode presents positive 12-month results from its Phase IIa clinical study in high-grade cervical dysplasia, providing proof of concept for its platform technology and drug candidate VB10.16.

April 2019

Nykode and Nektar Therapeutics present new preclinical data for VB10.NEO combined with bempegaldesleukin (NKTR-214) at the American Association for Cancer Research (AACR) Annual Meeting 2019.

June 2019

Nykode reports strong neoantigen-specific T cell responses induced in the first four cancer patients with low mutational burden after VB10.NEO vaccination.

November 2019

Nykode announces initial data showing positive clinical responses in patients with locally advanced or metastatic cancer treated with VB10.NEO and presents data at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2019) April 2020, expanding strategic focus to include infectious disease.

July 2020

Nykode doses first patient in Phase II clinical trial VB C-02 study with VB10.16 in combination atezolizumab.

August 2020

First patient dosed in the combination therapy of the Phase 1/2a study evaluating bempegaldesleukin, Nektar’s CD122-preferential IL-2 pathway agonist, with VB10.NEO, Nykode’s personalized neoantigen cancer vaccine, in patients with advanced squamous cell carcinoma of the head and neck (SCCHN).

August 2020

Nykode announces that it has reached the enrollment target of 50 patients and has finalized recruitment of patients to all study arms of its VB N-01 Phase I/IIa clinical trial of the personalized VB10.NEO neoantigen cancer vaccine.

October 2020

Nykode enters into a worldwide license and collaboration agreement with Genentech, a member of the Roche Group, to develop individualized neoantigen cancer vaccine.

June 2021

Nykode initiates a phase 1/2 trial to evaluate two second-generation SARS CoV-2 virus vaccine candidates.

July 2021

Nykode enters into a worldwide license agreement with Adaptive Biotechnologies for clinically validated SARS-CoV-2 T cell epitopes.

November 2021

Nykode enters into multi-target license and collaboration agreement with Regeneron to develop novel and innovative vaccines against cancer and infectious diseases.